Lundbeck eyes progress in 2022, disappoints compared to consensus
On Wednesday morning, Lundbeck has publicized its full-year financial figures for 2021. Sales of core products grew by 15 percent, but the company is still handing in results slightly below expectations.
by marketwire, translated by daniel pedersen
On Wednesday, pharmaceutical firm Lundbeck has released its full-year financial figures for 2021.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck's migraine drug approved in EU
For subscribers
